



Correction to: Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment

Martin Gabay¹ · Abraham Weizman^{2,3} · Nidal Zeineh¹ · Meygal Kahana¹ · Fadi Obeid¹ · Nahum Allon¹ · Moshe Gavish¹

Published online: 21 December 2021
© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to:
Cellular and Molecular Neurobiology
(2021) 41:1019–1029
<https://doi.org/10.1007/s10571-020-00969-1>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article unfortunately contained an error in the text under Materials and Methods section.

The sentence “The conjugated targeting peptide (1,2-dioleoyl-sn-glycero-3-succinate-Cys-HisLeu-Asp-Ile-Ile-Trp-COOH)” should read as “The conjugated targeting peptide (1,2-dioleoyl-sn-glycero-3-succinate-Ala-His-Arg-Glu-Arg-Met-Ser-COOH)”.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s10571-020-00969-1>.

✉ Moshe Gavish
mgavish@technion.ac.il

¹ The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096 Haifa, Israel

² Research Unit, Geha Mental Health Center and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, 4910002 Petah Tikva, Israel

³ Sackler Faculty of Medicine, Tel Aviv University, 6997801 Tel Aviv, Israel